Drug intelligence / Profile preview

Compound 28

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Compound 28 is an orally bioavailable small molecule that functions as a glutathione peroxidase 4 (GPX4) inhibitor. It has been investigated for its therapeutic potential in cancer, particularly in combination with CDK4/6 inhibitors such as palbociclib. By inhibiting GPX4, Compound 28 induces ferroptosis, a form of regulated cell death, in cancer cells. Preclinical studies have demonstrated its ability to reduce tumor sizes in xenograft models when administered alongside palbociclib.

Targets

GPX4 (Glutathione peroxidase 4)

Beyond the preview

Go deeper on Compound 28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound 28.

Explore the full profile